Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Baxter’s Heparin Problems May Have China Connection

publication date: Feb 14, 2008

Baxter’s heparin product, lately in the news because of recent side-effect problems, sourced its active pharmaceutical ingredient from a US supplier who, in turn, manufactured the drug in a China subsidiary. Even worse, the FDA was supposed to inspect the subsidiary, but some snafu prevented the inspection from ever taking place. So far in 2008, the FDA has received 350 reports of problems that may have been caused by Baxter’s heparin. Of the 350 incidents, 40% were termed serious, such as septic shock, and there are four deaths associated with the drug, though the causal link has not been definitively established. More details...

Stock Symbol: (NYSE: BAX) 



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here


BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here


Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here